Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression

Abstract Background Most patients with acute myeloid leukemia (AML) remain uncurable and require novel therapeutic methods. Gain-of-function FMS-like tyrosine kinase 3 (FLT3) mutations are present in 30–40% of AML patients and serve as an attractive therapeutic target. In addition, FLT3 is aberrantl...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Dengyang Zhang, Yao Guo, Yuming Zhao, Liuting Yu, Zhiguang Chang, Hanzhong Pei, Junbin Huang, Chun Chen, Hongman Xue, Xiaojun Xu, Yihang Pan, Ningning Li, Chengming Zhu, Zhizhuang Joe Zhao, Jian Yu, Yun Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-03-01
coleção:	Microbial Cell Factories
Assuntos:	FLT3 FL AML DM1 Targeted therapy
Acesso em linha:	https://doi.org/10.1186/s12934-021-01559-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!